Brief: Alzinova Gets Positive Feedback From Finnish Medicines Agency Fimea
15/10/2020 07:07
Oct 15 (Reuters) - Alzinova AB ALZ.ST :
* ALZINOVA AB (PUBL) HAS RECEIVED POSITIVE FEEDBACK FROM THE
FINNISH MEDICINES AGENCY FIMEA IN VIEW OF THE UPCOMING CLINICAL
TRIAL APPLICATION FOR THE ALZ-101 ALZHEIMER'S DISEASE VACCINE
* COMPANY INTENDS TO CONDUCT A CLINICAL FIRST-IN-HUMAN PHASE
1B
STUDY INPATIENTS SUFFERING FROM EARLY-ONSET ALZHEIMER'S DISEASE
* AIM IS TO INITIATE STUDY AND DOSE FIRST PATIENT DURING Q2
OF
2021
Source text for Eikon: ID:nWkr4lP8hw
Further company coverage: ALZ.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))